Diagnostic and Management Approach for Systemic Vasculitis
Introduction to Systemic Vasculitis
- Early diagnosis and aggressive treatment of systemic vasculitis are essential to reduce morbidity and mortality, with a diagnostic approach based on clinical presentation, laboratory testing, and often tissue biopsy for definitive diagnosis, as recommended by the European League Against Rheumatism 1, 2
Diagnostic Approach
- Antineutrophil cytoplasmic antibodies (ANCA) testing is highly specific for small-vessel vasculitides, with anti-PR3 ANCA (c-ANCA) associated with Wegener's granulomatosis and anti-MPO ANCA (p-ANCA) associated with microscopic polyangiitis, according to the American College of Rheumatology 1
- The European Vasculitis Study Group (EUVAS) classification includes localized, early systemic, generalized, and severe renal disease categories, which can guide treatment decisions 1
Disease Classification
- Small vessel vasculitis includes ANCA-associated vasculitis (granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis), as defined by the International Chapel Hill Consensus Conference 1
Management Approach
- Treatment should be guided by disease severity, organ involvement, and patient factors, with mortality in vasculitis ranging from 0-25% at 1 year depending on disease severity, as reported by the European League Against Rheumatism 1
- High-dose corticosteroids (methylprednisolone 1-2 mg/kg/day) are recommended as initial therapy for severe or life-threatening disease, according to the American College of Rheumatology 4
- Cyclophosphamide is recommended for induction therapy in severe cases, as suggested by the European Vasculitis Study Group 4